Latest disclosed round
Series D
- Date
- 2021-04-01
- Amount
- USD 225m
- Sector
- Biotech & techbio
- Companies House
- 13483814
Later stage / growth
Exscientia
AI drug discovery
ReviewSeries DOxford
Evidence status
Review retained
- Identity
- Review
- Match
- Review required
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
11 linked investors
Air Street CapitalparticipantBlackRockparticipantBristol Myers SquibbparticipantCasdin CapitalparticipantFarallon CapitalparticipantGT Healthcare CapitalparticipantMarshall WaceparticipantMubadala Investment CompanyparticipantNovo HoldingsparticipantPivotal bioVenture PartnersparticipantSoftBank Vision Fund 2lead
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2021-04-01 | Series D | $225M equity (plus up to $300M SoftBank commitment; up to $525M total) | SoftBank Vision Fund 2, Novo Holdings, BlackRock, Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Bristol Myers Squibb |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.